SAN DIEGO and SYDNEY, Australia, Nov. 21, 2011 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce that its Chairman and CEO, Robert Stockman, is presenting at the 23rd Annual Piper Jaffray Health Care Conference at 10:30 a.m. US EST on Tuesday, November 29, 2011. The conference is being held November 29 and 30, 2011 at The New York Palace in New York City.
The information contained in the presentation has been previously disclosed. Copies of REVA’s recent public presentations may be accessed under the Investor Relations section of REVA’s website at www.revamedical.com.
About REVA
REVA is a development stage medical device company incorporated in Delaware, USA, that is focused on the development and eventual commercialisation of its proprietary, bioresorbable stent products. REVA’s lead product, the ReZolve™ stent, combines REVA’s proprietary stent design with a proprietary polymer that is metabolised and cleared from the body. The ReZolve stent is designed to offer full x-ray visibility, clinically relevant sizing and a controlled and safe resorption rate. In addition, by early encapsulation of the stent in the artery tissue coupled with the loss of stent structure over time, the ReZolve stent may reduce the incidence of late forming blood clots, or thrombosis, a rare but serious problem associated with drug-eluting metal stents currently on the market. REVA is in the process of finalising the design of its ReZolve stent and will require clinical results and regulatory approval before it can begin selling the ReZolve stent.
The REVA Medical, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8505
CONTACT: United States
Investor and Media Enquiries:
Cheryl Liberatore
Director, Investor Relations and Marketing
REVA Medical, Inc.
+1 858 966-3045
Australia
Investor Enquiries:
David Allen or Alan Taylor
Inteq Limited
+61 2 9231 3322
Media Enquiries:
Kyahn Williamson & Rebecca Wilson
Buchan Consulting
+ 61 3 9866 4722